SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy

This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).

NCT Number	NCT07524374
Lead Sponsor	Zhigang Li Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions	ESCC
Enrollment	33 participants
Start Date	2026-03-15
Primary Completion	2027-09-30 (estimated)
Study Completion	2028-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-13